Nocodazole [31430-18-9]

Commande minimum 2

Référence T2802-10mg

Conditionnement : 10mg

Marque : TargetMol

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Nocodazole

(Synonyms: R17934, Oncodazole) Copy Product Info
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
Nocodazole
Cas No. 31430-18-9
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.91%
Color:White to Yellow

Product Introduction

Bioactivity
Description
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
Targets & IC50
Abl:0.21 μM, c-Kit:1.6 μM (Kd), Abl (E255K):0.53 μM, MET:1.7 μM (Kd), B-Raf:1.8 μM (Kd), PI3Kγ:1.5 μM (Kd), MEK2:1.6 μM (Kd), MEK1:1.7 μM (Kd), Abl (T315I):0.64 μM, B-Raf (V600E):1.1 μM (Kd)
In vitro
METHODS: Erythrocytes were treated with Nocodazole (15-60 µg/mL) for 48 h. Phosphatidylserine was detected using Annexin-V-FITC.
RESULTS: Nocodazole treatment increased the percentage of phosphatidylserine exposed to erythrocytes, reaching statistical significance at 30 µg/mL. [1]
METHODS: hESCs cells were treated with Nocodazole (100 ng/mL) for 16 h and cell cycle profiles were analyzed using Flow Cytometry.
RESULTS: Nocodazole treatment synchronized the cell cycle (>90% of cells in G2/M), while cells remained synchronized after release and moved evenly through the cell cycle for 24 h. At 2 h after removal of Nocodazole, the cells entered the G1 phase, with 70% of the cells in the G1 phase after 4 h, and 80% in the S phase after 12 h. The cells were treated with Nocodazole (100 ng/mL) for 16 h, and the cell cycle was analyzed by Flow Cytometry. [2]
In vivo
METHODS: To detect anti-tumor activity in vivo, Nocodazole (12 mg/kg three times a week) and dexamethasone (2 mg/kg twice a week) were injected intraperitoneally for fifteen days into immunodeficient mice bearing myeloma H929.
RESULTS: Nocodazole in combination with dexamethasone significantly inhibited myeloma tumor growth and prolonged survival. [3]
METHODS: To study the effects on intestinal mucositis, Nocodazole (5 mg/kg) and ketoconazole (50 mg/kg) were administered intraperitoneally three times a week for six weeks to nude mice harboring the human colorectal cancer tumor COLO 205.
RESULTS: The antitumor effect of Nocodazole was significantly enhanced after six weeks of ketoconazole treatment. [4]
SynonymsR17934, Oncodazole
Cell Research
Nocodazole is dissolved in a final concentration of 0.05% DMSO. Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading.
Chemical Properties
Molecular Weight301.32
FormulaC14H11N3O3S
Cas No.31430-18-9
SmilesCOC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1
Relative Density.1.49 g/cm3
Storage & Solubility Information
StorageStore at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 20 mg/mL (66.37 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.64 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.3187 mL16.5937 mL33.1873 mL165.9365 mL
5 mM0.6637 mL3.3187 mL6.6375 mL33.1873 mL
10 mM0.3319 mL1.6594 mL3.3187 mL16.5937 mL
20 mM0.1659 mL0.8297 mL1.6594 mL8.2968 mL
50 mM0.0664 mL0.3319 mL0.6637 mL3.3187 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
T3015-10mg
 10mg